Incyte | INCY - Ebitda


Incyte reported $778.57M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 222.32M 76.27M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Exelixis USD 275.36M 19.96M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -687M 571M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Novartis USD 5.36B 45M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026